# 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

> **NCT05197270** · PHASE1,PHASE2 · RECRUITING · sponsor: **4D Molecular Therapeutics** · enrollment: 215 (estimated)

## Conditions studied

- Neovascular (Wet) Age-Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** 4D-150 IVT
- **BIOLOGICAL:** Aflibercept IVT

## Key facts

- **NCT ID:** NCT05197270
- **Lead sponsor:** 4D Molecular Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-09
- **Primary completion:** 2027-03
- **Final completion:** 2031-01
- **Target enrollment:** 215 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05197270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05197270, "4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05197270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*